Malaysian pharmaceutical company to produce COVID-19 adenoviral vector vaccine with Chinese technology

Malaysian pharmaceutical company Solution Biologics deputy group managing director Mohd Nazlee Kamal speaks during an interview with Xinhua at Solution Biologics factory in Kuala Lumpur, Malaysia, Sept. 8, 2021. Chinese company CanSino Biologics has helped Malaysia cross another milestone in vaccine manufacturing, this time by transferring technology to enable the local "fill and finish" of the COVID-19 vaccine based on the adenovirus platform. Malaysian pharmaceutical company Solution Biologics deputy group managing director Mohd Nazlee Kamal told Xinhua that close and friendly cooperation with CanSino has made the venture possible. (Photo by Chong Voon Chung/Xinhua)